trending Market Intelligence /marketintelligence/en/news-insights/trending/4hzshp6n0izvzsczzu0ylg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

India's Zydus Healthcare acquires six drug brands from Merck

Mining Exploration Insights – May 2020

Essential Energy Insights - May 14, 2020

Paypal Well-Positioned To Gain Share In COVID-Related Digital Payments Shift

Credit Analytics Case Study: Provogue (India) Limited and Shree Renuka Sugars

India's Zydus Healthcare acquires six drug brands from Merck

India's Zydus Healthcare Ltd. acquired six brands from Merck & Co. Inc. that fall under the categories of men's health, women's health, wound management and cardiovascular therapy.

The brands are Deca-Durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten, which had sales of 840 million Indian rupees in 2015.

The companies did not disclose the financial terms of the acquisition.

As of Dec. 28, US$1 was equivalent to 68.21 Indian rupees.